Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Net Cash Flow: 2020-2025

Historic Net Cash Flow for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to -$4.1 million.

  • Janux Therapeutics' Net Cash Flow fell 133.55% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.6 million, marking a year-over-year increase of 125.32%. This contributed to the annual value of $411.4 million for FY2024, which is 1376.81% up from last year.
  • As of Q3 2025, Janux Therapeutics' Net Cash Flow stood at -$4.1 million, which was up 80.95% from -$21.3 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Net Cash Flow ranged from a high of $403.9 million in Q4 2024 and a low of -$356.9 million during Q1 2025.
  • For the 3-year period, Janux Therapeutics' Net Cash Flow averaged around -$276,091, with its median value being -$4.1 million (2025).
  • As far as peak fluctuations go, Janux Therapeutics' Net Cash Flow plummeted by 18,917.56% in 2021, and later soared by 19,571.26% in 2024.
  • Over the past 5 years, Janux Therapeutics' Net Cash Flow (Quarterly) stood at -$3.0 million in 2021, then plummeted by 345.54% to -$13.3 million in 2022, then spiked by 115.41% to $2.1 million in 2023, then skyrocketed by 19,571.26% to $403.9 million in 2024, then slumped by 133.55% to -$4.1 million in 2025.
  • Its Net Cash Flow was -$4.1 million in Q3 2025, compared to -$21.3 million in Q2 2025 and -$356.9 million in Q1 2025.